Bain Capital

HealthEdge is a technology company that provides an integrated software platform designed for healthcare payors. Founded in December 2004 by Albert Waxman and Rob Gillette, HealthEdge specializes in delivering innovative solutions that help health insurers enhance operational efficiency, improve patient outcomes, and significantly lower administrative costs. The company's flagship product suite, HealthRules, is built on patented technology and can be deployed via the HealthEdge Cloud or on-premises. This platform encompasses various functionalities, including claims and benefits administration, care management, and business intelligence, enabling clients to adopt new business models and streamline processes within the healthcare delivery system. In 2012, HealthEdge expanded its offerings by acquiring Click4Care, which enhanced its capabilities in clinical care management. Headquartered in Burlington, Massachusetts, HealthEdge also has a research and development center in Powell, Ohio.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston that specializes in developing treatments for serious ophthalmic conditions. The company's primary focus is on addressing untreatable diseases of the eye, with its lead drug candidate being an orally delivered compound aimed at treating Stargardt disease and age-related macular degeneration. Through its innovative approach, Alkeus aims to empower medical professionals to manage symptoms of irreversible vision loss at an earlier stage in affected patients.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Oort is an identity threat detection and response platform focused on enhancing enterprise security. Recognizing that over 60% of security breaches involve the abuse of valid identity credentials, Oort positions identity as a critical aspect of cybersecurity. The company offers a Software as a Service (SaaS) platform that allows cybersecurity and IT professionals to efficiently manage their identity and access management (IAM) programs. With a quick deployment process and a focus on reducing identity vulnerabilities at scale, Oort provides organizations with enhanced visibility and control over their identity attack surface. It operates as a fully remote startup based in Boston, MA, and its innovative solutions help clients secure their digital supply chains. Oort is supported by prominent investors and aims to equip security teams with the tools needed to combat identity threats effectively.

Oort is an identity threat detection and response platform focused on enhancing enterprise security. Recognizing that over 60% of security breaches involve the abuse of valid identity credentials, Oort positions identity as a critical aspect of cybersecurity. The company offers a Software as a Service (SaaS) platform that allows cybersecurity and IT professionals to efficiently manage their identity and access management (IAM) programs. With a quick deployment process and a focus on reducing identity vulnerabilities at scale, Oort provides organizations with enhanced visibility and control over their identity attack surface. It operates as a fully remote startup based in Boston, MA, and its innovative solutions help clients secure their digital supply chains. Oort is supported by prominent investors and aims to equip security teams with the tools needed to combat identity threats effectively.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

HYCU is a leading provider of multi-cloud data protection as a service, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's innovative R-Cloud platform delivers effective data protection, migration, disaster recovery, and ransomware protection, simplifying the process for thousands of organizations globally. By eliminating the complexities and costs associated with traditional data protection solutions, HYCU has established itself as a top choice in the SaaS data protection industry. The company is based in Boston, Massachusetts, and has achieved a notable Net Promoter Score reflecting high customer satisfaction. To date, HYCU has raised significant venture capital funding to support its growth and development in the competitive data management market.

Hometap, founded in 2018 and based in Boston, Massachusetts, is a fintech company that specializes in home equity investments. It allows homeowners to access funds immediately without taking on loans or selling their homes. Homeowners can use these funds for various purposes such as paying off debt or making renovations, all while avoiding added debt or monthly payments. Hometap provides this cash in exchange for a percentage of the future appreciation of the home's value.

Bain Capital, established in 1984, is a global multi-asset alternative investment firm with over $100 billion in assets under management. Headquartered in Boston, Massachusetts, the firm operates through several business units: Private Equity, Public Equity, Credit, and Venture Capital. Bain Capital Private Equity invests in various sectors, including consumer, healthcare, industrials, and technology, across North America, Europe, and Asia. Bain Capital Ventures, the venture capital arm, focuses on seed to growth-stage investments in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Life Sciences, a dedicated life sciences investment platform, invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Bain Capital Double Impact, the firm's impact investing arm, builds great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

ConvenientMD LLC is an urgent care provider that specializes in treating non-life-threatening injuries and illnesses. Founded in 2011 and based in Portsmouth, New Hampshire, the company offers a range of services including treatment for sprains, strains, fractures, cuts, colds, bronchitis, and various infections. Additionally, ConvenientMD provides preventive care such as physicals, immunizations, and on-site prescriptions, along with X-ray and laboratory services. Patients can access care without an appointment, with centers open daily from 8 am to 8 pm, ensuring prompt service with minimal wait times. The company operates multiple locations across New Hampshire, Maine, and Massachusetts, emphasizing high-quality medical care delivered by a professional team using advanced medical equipment.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

HYCU is a leading provider of multi-cloud data protection as a service, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's innovative R-Cloud platform delivers effective data protection, migration, disaster recovery, and ransomware protection, simplifying the process for thousands of organizations globally. By eliminating the complexities and costs associated with traditional data protection solutions, HYCU has established itself as a top choice in the SaaS data protection industry. The company is based in Boston, Massachusetts, and has achieved a notable Net Promoter Score reflecting high customer satisfaction. To date, HYCU has raised significant venture capital funding to support its growth and development in the competitive data management market.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Hi Marley, Inc., founded in 2017 and based in Boston, Massachusetts, offers a conversational platform tailored for the insurance industry. Their flagship product, Marley, facilitates connections between insurance companies and customers through intelligent messaging and human interaction. The platform enables insurers to engage with clients via messaging, update them on policies, and address routine inquiries efficiently. Hi Marley serves auto, home, and business insurance companies, aiming to enhance customer satisfaction and operational productivity by streamlining communication around claims, underwriting, and policyholder services.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

TeachTown Inc. is an educational company that specializes in developing solutions for children diagnosed with autism spectrum disorder, developmental disabilities, intellectual disabilities, and emotional and behavioral disorders. Founded in 2001 and based in Woburn, Massachusetts, TeachTown offers programs such as TeachTown Basics, a computer-delivered and teacher-led instructional program that enhances vocabulary, listening skills, social-emotional development, and cognitive abilities. Additionally, TeachTown Social Skills provides an online curriculum featuring character-based video modeling to help elementary and middle school students develop essential social skills. The company also supports educators through professional development resources aimed at teachers, paraprofessionals, specialists, and administrators. TeachTown serves a diverse clientele, including schools, families, and clinicians, by providing engaging educational tools designed to improve the academic and behavioral functioning of students with special needs.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nebulous, Inc. is a technology company focused on developing blockchain hardware and software infrastructure for the decentralized internet. Founded in 2014 and based in Boston, Massachusetts, the company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a data storage marketplace. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform tailored for developers, along with SiaStream, which provides affordable storage solutions for media files, enabling fast streaming. As a core contributor to the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Hi Marley, Inc., founded in 2017 and based in Boston, Massachusetts, offers a conversational platform tailored for the insurance industry. Their flagship product, Marley, facilitates connections between insurance companies and customers through intelligent messaging and human interaction. The platform enables insurers to engage with clients via messaging, update them on policies, and address routine inquiries efficiently. Hi Marley serves auto, home, and business insurance companies, aiming to enhance customer satisfaction and operational productivity by streamlining communication around claims, underwriting, and policyholder services.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nebulous, Inc. is a technology company focused on developing blockchain hardware and software infrastructure for the decentralized internet. Founded in 2014 and based in Boston, Massachusetts, the company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a data storage marketplace. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform tailored for developers, along with SiaStream, which provides affordable storage solutions for media files, enabling fast streaming. As a core contributor to the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.

TruVideo is a technology company based in Wellesley, Massachusetts, founded in 2015. It specializes in developing a proprietary video and texting platform tailored for auto repair shops. The TruVideo application allows technicians to record custom videos of vehicle conditions and servicing, which can be shared with customers via web links. This feature enhances transparency and builds customer trust. Additionally, the platform supports text messaging and mobile pay services, enabling users to approve repairs and make payments seamlessly. By facilitating clear communication between service providers and customers, TruVideo helps improve customer engagement and satisfaction in the automotive sector.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Rocket Software, Inc. is a provider of enterprise software solutions that focuses on IT modernization and automation services. Established in 1990 and headquartered in Waltham, Massachusetts, the company offers a wide range of products including application lifecycle management, business intelligence, data migration, enterprise performance management, and mainframe modernization. It serves numerous industries, such as automotive, healthcare, finance, and technology, providing tools and services that help businesses optimize their infrastructure, data, and applications. Additionally, Rocket Software offers training, technical support, and professional services to help clients navigate complex IT challenges and enhance their operational capabilities. With a global presence across North America, Europe, and the Asia-Pacific region, Rocket Software is committed to delivering innovative solutions tailored to meet the evolving needs of its diverse customer base.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

ObserveIT LTD. is a provider of insider threat management software solutions, specializing in detecting, investigating, and preventing insider threats within organizations. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company serves a diverse range of industries, including financial services, technology, and manufacturing. Its platform allows organizations to monitor user activity, detect data loss, and respond to incidents more efficiently, significantly reducing investigation times from days to minutes. By offering comprehensive solutions for security teams, ObserveIT aims to enhance the identification of insider threats, streamline investigative processes, and facilitate compliance, ultimately helping organizations safeguard sensitive information and mitigate risks associated with insider actions. ObserveIT operates as a subsidiary of Proofpoint, Inc.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

ObserveIT LTD. is a provider of insider threat management software solutions, specializing in detecting, investigating, and preventing insider threats within organizations. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company serves a diverse range of industries, including financial services, technology, and manufacturing. Its platform allows organizations to monitor user activity, detect data loss, and respond to incidents more efficiently, significantly reducing investigation times from days to minutes. By offering comprehensive solutions for security teams, ObserveIT aims to enhance the identification of insider threats, streamline investigative processes, and facilitate compliance, ultimately helping organizations safeguard sensitive information and mitigate risks associated with insider actions. ObserveIT operates as a subsidiary of Proofpoint, Inc.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

BevSpot, Inc. is a Boston-based company that develops an online platform for the food and beverage industry, focusing on inventory management. Incorporated in 2014, BevSpot offers an all-in-one software solution that streamlines various operational aspects, including inventory, ordering, invoicing, and sales data analysis. This cloud-based platform allows bars and restaurants to manage their operations efficiently from any device, ensuring that critical data is accessible and securely stored. By enabling food and beverage establishments to make informed, data-driven decisions, BevSpot aims to enhance operational efficiency and support business growth within the sector.

Semantic Machines develops advanced artificial intelligence technology focused on conversational AI. Based in Newton, Massachusetts, with additional offices in Berkeley and Boston, the company specializes in creating systems that enable computers to understand, communicate, and collaborate effectively with humans. Their technology includes components like a Conversation Engine for modeling human discourse, neural network systems for semantic analysis and dialog state management, speech recognition and synthesis platforms, and reinforcement learning technologies. Semantic Machines aims to revolutionize human-computer interaction by making conversational computing scalable and viable, thereby enhancing customer service and home automation experiences.

SevOne, Inc. is a provider of infrastructure performance monitoring and analytics solutions, catering to a global clientele that includes communications service providers, financial services, and large enterprises. Founded in 2003 and headquartered in Boston, Massachusetts, with additional offices in Newark, Delaware, and London, the company focuses on delivering real-time insights through its SevOne Data Platform, which collects and analyzes multi-vendor network performance metrics. Its offerings include customizable visualization tools, network streaming telemetry, and solutions for software-defined networking and SD-WAN monitoring. The patented SevOne Cluster architecture enables rapid monitoring across diverse devices, ensuring that organizations can prevent performance-impacting outages. SevOne's technology is designed to support complex, dynamic infrastructures, helping clients navigate the challenges of next-generation networking. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.

Founded in 1996, Blue Coat is now an industry leader in the field of advanced enterprise security. Originally founded as CacheFlow, the company changed its name to Blue Coat in 2002 to reflect its new emphasis on enterprise security, invoking the image of a baseball umpire’s uniform. In March 2015, Blue Coat was acquired by private equity firm Bain Capital. Blue Coat provides advanced enterprise security for 15,000 organizations across the globe, numbering 88 of the 100 largest global companies among them. The Blue Coat Security Platform provides an integrated platform that addresses companies’ network, security, and cloud requirements. This allows customers a minimal impact on network performance while still providing top-quality protection against advanced threats and improving performance for cloud applications and services. Blue Coat focuses strongly on growth and innovation, with 200 patents issued and pending. Blue Coat also maintains several Research and Development centers across the globe, with facilities in Sunnyvale, California; Draper, Utah; Waterloo, Ontario; Boxborough, Massachusetts; and Lysaker, Norway. The company also providers 24/7 “Follow the Sun” Model Global Support from each of its six support centers. Particularly in recent years, Blue Coat has achieved significant positive recognition within the industry, receiving many awards. Among these accolades are the Frost & Sullivan 2016 Global Network Security Forensics Market Leadership Award; the Frost & Sullivan 2014 Web Security Vendor of the Year Award; the 2015 Cloud Computing Magazine Cloud Computing Excellence Award; and the 2015 Best Cloud Computing Security Solution, Reader Trust Award from SC Magazine.

Turbonomic is a Boston-based software provider specializing in Application Resource Management (ARM) and Network Performance Management (NPM). The company offers AI-powered technology designed to optimize application performance, compliance, and cost in real time. Its hybrid cloud management platform integrates with leading application performance management and IT service management solutions, creating a unified control plane for automating IT resource management. By dynamically adjusting resource supply based on workload demand, Turbonomic enables organizations to maintain optimal application health across on-premises and multi-cloud environments. This capability allows businesses to self-manage their IT resources in real time, ensuring performance while reducing costs.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

Manicube is a service-oriented company that aims to enhance the lives of working women by transforming personal care services. It specializes in providing quick and affordable manicure services directly at the workplace, catering to busy professionals. By partnering with corporate HR departments, Manicube facilitates licensed nail technicians to deliver 15-minute manicures in convenient locations such as conference rooms or employee service areas. The company's offerings extend beyond manicures to include male grooming services, thus addressing a wider audience within the corporate environment. Customers can easily manage their appointments through the company's website, allowing them to book, modify, and pay for services seamlessly. Operating in key markets including New York City, Chicago, San Francisco, and Boston, Manicube is dedicated to making personal care accessible to professionals during their workday.

ObserveIT LTD. is a provider of insider threat management software solutions, specializing in detecting, investigating, and preventing insider threats within organizations. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company serves a diverse range of industries, including financial services, technology, and manufacturing. Its platform allows organizations to monitor user activity, detect data loss, and respond to incidents more efficiently, significantly reducing investigation times from days to minutes. By offering comprehensive solutions for security teams, ObserveIT aims to enhance the identification of insider threats, streamline investigative processes, and facilitate compliance, ultimately helping organizations safeguard sensitive information and mitigate risks associated with insider actions. ObserveIT operates as a subsidiary of Proofpoint, Inc.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

SevOne, Inc. is a provider of infrastructure performance monitoring and analytics solutions, catering to a global clientele that includes communications service providers, financial services, and large enterprises. Founded in 2003 and headquartered in Boston, Massachusetts, with additional offices in Newark, Delaware, and London, the company focuses on delivering real-time insights through its SevOne Data Platform, which collects and analyzes multi-vendor network performance metrics. Its offerings include customizable visualization tools, network streaming telemetry, and solutions for software-defined networking and SD-WAN monitoring. The patented SevOne Cluster architecture enables rapid monitoring across diverse devices, ensuring that organizations can prevent performance-impacting outages. SevOne's technology is designed to support complex, dynamic infrastructures, helping clients navigate the challenges of next-generation networking. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.

ScaleBase, Inc. is a database scalability company that specializes in providing a virtual database consolidation layer, facilitating instant scaling of application and database infrastructure. Founded in 2009 and based in Newton, Massachusetts, ScaleBase offers the Data Traffic Manager, a middleware solution that effectively manages and scales databases while balancing load between database applications and their backend instances. The company focuses on enabling next-generation applications that require robust transactional processing without necessitating changes to existing systems. By virtualizing distributed database environments, ScaleBase simplifies operations, enhances real-time elasticity, and improves availability for various sectors, including SaaS, online gaming, digital media, social networks, and enterprises. As of 2015, ScaleBase operates as a subsidiary of ScaleArc Inc.

Turbonomic is a Boston-based software provider specializing in Application Resource Management (ARM) and Network Performance Management (NPM). The company offers AI-powered technology designed to optimize application performance, compliance, and cost in real time. Its hybrid cloud management platform integrates with leading application performance management and IT service management solutions, creating a unified control plane for automating IT resource management. By dynamically adjusting resource supply based on workload demand, Turbonomic enables organizations to maintain optimal application health across on-premises and multi-cloud environments. This capability allows businesses to self-manage their IT resources in real time, ensuring performance while reducing costs.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

Dynatrace, Inc. is a software intelligence company that offers a comprehensive platform for managing and optimizing enterprise cloud applications. The Dynatrace platform enables users to monitor and analyze their entire IT infrastructure, providing insights into application performance, user experience, and operational efficiency. Its product suite includes tools for monitoring various application environments, such as mobile and web applications, as well as network services. Additionally, Dynatrace provides solutions for real user monitoring and synthetic monitoring to ensure application availability and performance. The platform’s advanced capabilities support customers in modernizing IT operations, accelerating software delivery, and enhancing digital experiences. Dynatrace serves a diverse range of industries, including banking, insurance, retail, and manufacturing, and operates globally with a strong presence in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company is headquartered in Waltham, Massachusetts.

Memento is a provider of enterprise fraud and compliance solutions, catering primarily to credit unions and community banks in North America and Europe. Founded in 2002 and headquartered in Concord, Massachusetts, with additional offices in major cities including New York, Los Angeles, Milan, London, and Washington, D.C., Memento designs its offerings to enhance proactive monitoring, detection, and investigation of fraudulent activities. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management functionalities to address various technological challenges and combat fraud and compliance issues. Memento's solutions encompass monitoring for new account fraud across multiple channels, insider threats through transaction data analysis, and protecting deposit accounts from fraud. Additionally, it provides tailored fraud prevention solutions for smaller financial institutions and tools that help organizations meet regulatory requirements while safeguarding customers against identity theft.

Boston Heart Diagnostics is a healthcare company based in Framingham, Massachusetts, specializing in cardiovascular disease management. The company offers a comprehensive range of laboratory techniques, including gas chromatography, gel electrophoresis, genetic testing, and liquid chromatography. Its proprietary lipid testing technology enables ongoing monitoring of patients' conditions and facilitates the precise selection of effective pharmaceutical treatments for dyslipidemia. Unlike traditional lipid testing methods that focus primarily on initial screenings and may take up to six months to assess treatment efficacy, Boston Heart's approach allows for evaluations within the first six weeks. By combining advanced therapy guidelines and patient support services, Boston Heart Diagnostics aims to provide personalized treatment options that enhance patient health and improve disease management outcomes.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

Enservio is the market leader in property insurance affinity solutions, strategic analytics, and contents software, inventory, valuation, replacement and replacement tools. Enservio created the first SaaS (software as a service) software platform for contents, the first replacement mall, the first payment debit card for claims and the first ContentsITV product. We provide software and services to property insurance carriers and their policy holders nationwide. Founded in 2004, we are headquartered near Boston, in Needham, MA with offices and professional staff across the United States.

Memento is a provider of enterprise fraud and compliance solutions, catering primarily to credit unions and community banks in North America and Europe. Founded in 2002 and headquartered in Concord, Massachusetts, with additional offices in major cities including New York, Los Angeles, Milan, London, and Washington, D.C., Memento designs its offerings to enhance proactive monitoring, detection, and investigation of fraudulent activities. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management functionalities to address various technological challenges and combat fraud and compliance issues. Memento's solutions encompass monitoring for new account fraud across multiple channels, insider threats through transaction data analysis, and protecting deposit accounts from fraud. Additionally, it provides tailored fraud prevention solutions for smaller financial institutions and tools that help organizations meet regulatory requirements while safeguarding customers against identity theft.

Rapid7, established in 2000, is a cybersecurity company that offers a range of solutions to help organizations proactively manage their security. Initially focusing on vulnerability management, the company has since expanded its portfolio to include detection and response, security information and event management, cloud security, threat intelligence, application security, and security orchestration, automation, and response. Rapid7 empowers businesses with visibility and insights to make informed security decisions, create action plans, and monitor progress. The company, based in Boston, is committed to helping organizations enhance their security posture and is actively involved in the cybersecurity community.

Dynatrace, Inc. is a software intelligence company that offers a comprehensive platform for managing and optimizing enterprise cloud applications. The Dynatrace platform enables users to monitor and analyze their entire IT infrastructure, providing insights into application performance, user experience, and operational efficiency. Its product suite includes tools for monitoring various application environments, such as mobile and web applications, as well as network services. Additionally, Dynatrace provides solutions for real user monitoring and synthetic monitoring to ensure application availability and performance. The platform’s advanced capabilities support customers in modernizing IT operations, accelerating software delivery, and enhancing digital experiences. Dynatrace serves a diverse range of industries, including banking, insurance, retail, and manufacturing, and operates globally with a strong presence in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company is headquartered in Waltham, Massachusetts.

Bright Horizons Family Solutions is a prominent provider of early education and childcare services, established in 1986 and headquartered in Newton, Massachusetts. The company specializes in delivering high-quality educational programs, employer-sponsored childcare, backup care, and educational advisory services, all designed to accommodate modern family and work dynamics. Bright Horizons is dedicated to nurturing each child's unique qualities and potential while fostering strong partnerships with families. In collaboration with employers, the company aims to create family-friendly workplaces and promote an environment that encourages professionalism, growth, and diversity. Through its comprehensive offerings, Bright Horizons strives to support the needs of children and families, while maintaining a financially robust organization.

Skyhook is a Boston-based mobile location services company, founded in 2003, that specializes in hybrid positioning technology. Initially focused on geolocating Wi-Fi access points, the company has since expanded its offerings to include advanced location services that integrate Wi-Fi, GPS, cell towers, IP addresses, and device sensors. In 2015, Skyhook introduced Behavioral Data through an open platform, prioritizing data privacy and security for its advertising and application clients. The company further developed its technology in 2016 with the launch of Precision Location to support wearables and the Internet of Things (IoT), alongside products such as Personas and Context Accelerator, which assist brands in effectively engaging mobile consumers.

Memento is a provider of enterprise fraud and compliance solutions, catering primarily to credit unions and community banks in North America and Europe. Founded in 2002 and headquartered in Concord, Massachusetts, with additional offices in major cities including New York, Los Angeles, Milan, London, and Washington, D.C., Memento designs its offerings to enhance proactive monitoring, detection, and investigation of fraudulent activities. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management functionalities to address various technological challenges and combat fraud and compliance issues. Memento's solutions encompass monitoring for new account fraud across multiple channels, insider threats through transaction data analysis, and protecting deposit accounts from fraud. Additionally, it provides tailored fraud prevention solutions for smaller financial institutions and tools that help organizations meet regulatory requirements while safeguarding customers against identity theft.

Dynatrace, Inc. is a software intelligence company that offers a comprehensive platform for managing and optimizing enterprise cloud applications. The Dynatrace platform enables users to monitor and analyze their entire IT infrastructure, providing insights into application performance, user experience, and operational efficiency. Its product suite includes tools for monitoring various application environments, such as mobile and web applications, as well as network services. Additionally, Dynatrace provides solutions for real user monitoring and synthetic monitoring to ensure application availability and performance. The platform’s advanced capabilities support customers in modernizing IT operations, accelerating software delivery, and enhancing digital experiences. Dynatrace serves a diverse range of industries, including banking, insurance, retail, and manufacturing, and operates globally with a strong presence in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company is headquartered in Waltham, Massachusetts.

aPriori Technologies Inc. develops and markets product cost management software solutions aimed at enhancing profitability and accelerating time to market for manufacturers. Founded in 2003 and based in Concord, Massachusetts, with an additional office in Belfast, Northern Ireland, aPriori's enterprise platform assists manufacturers and their suppliers in managing and controlling product costs throughout their organizations. By utilizing digital manufacturing simulation and digital twin technologies, aPriori provides insights into design for manufacturability and design to cost, facilitating collaboration across the product development process. The company's offerings include strategy development, deployment planning, process implementation, education and training, and technical support. aPriori serves a diverse range of sectors, including industrial machinery, aerospace and defense, automotive, and high technology. Its solutions enable clients to make informed design, sourcing, and manufacturing decisions, leading to significant cost reductions both before and after production.

Skyhook is a Boston-based mobile location services company, founded in 2003, that specializes in hybrid positioning technology. Initially focused on geolocating Wi-Fi access points, the company has since expanded its offerings to include advanced location services that integrate Wi-Fi, GPS, cell towers, IP addresses, and device sensors. In 2015, Skyhook introduced Behavioral Data through an open platform, prioritizing data privacy and security for its advertising and application clients. The company further developed its technology in 2016 with the launch of Precision Location to support wearables and the Internet of Things (IoT), alongside products such as Personas and Context Accelerator, which assist brands in effectively engaging mobile consumers.

Memento is a provider of enterprise fraud and compliance solutions, catering primarily to credit unions and community banks in North America and Europe. Founded in 2002 and headquartered in Concord, Massachusetts, with additional offices in major cities including New York, Los Angeles, Milan, London, and Washington, D.C., Memento designs its offerings to enhance proactive monitoring, detection, and investigation of fraudulent activities. The company’s flagship platform, Security 4.0, integrates data management, fraud analytics, and case management functionalities to address various technological challenges and combat fraud and compliance issues. Memento's solutions encompass monitoring for new account fraud across multiple channels, insider threats through transaction data analysis, and protecting deposit accounts from fraud. Additionally, it provides tailored fraud prevention solutions for smaller financial institutions and tools that help organizations meet regulatory requirements while safeguarding customers against identity theft.

aPriori Technologies Inc. develops and markets product cost management software solutions aimed at enhancing profitability and accelerating time to market for manufacturers. Founded in 2003 and based in Concord, Massachusetts, with an additional office in Belfast, Northern Ireland, aPriori's enterprise platform assists manufacturers and their suppliers in managing and controlling product costs throughout their organizations. By utilizing digital manufacturing simulation and digital twin technologies, aPriori provides insights into design for manufacturability and design to cost, facilitating collaboration across the product development process. The company's offerings include strategy development, deployment planning, process implementation, education and training, and technical support. aPriori serves a diverse range of sectors, including industrial machinery, aerospace and defense, automotive, and high technology. Its solutions enable clients to make informed design, sourcing, and manufacturing decisions, leading to significant cost reductions both before and after production.

Network Intelligence Corporation provides security information and event management solutions. Its products include enVision that collects and protects data, as well as provides security and compliance analysis, and reporting and alerting solutions; Intelligence Engine software/hardware network security appliances for security information and event management market; and LogSmart Internet Protocol Database, which provides architecture to collect and protect the data from various Internet protocol devices. The company's strategic partners include Microsoft; NetworkAppliance; IBM; EMC2; EDS; Check Point Software Technologies, Ltd.; and Juniper Networks. Network Intelligence Corporation was formerly known as OpenSystems.com, Inc. and changed its name to Network Intelligence Corporation. The company was founded in 1996 and is headquartered in Westwood, Massachusetts. It also has offices in Rancho Santa Margarita, California; Chicago, Illinois; Alpharetta, Georgia; Seabrook, Texas; Arlington, Virginia; Amsterdam, the Netherlands; Paris, France; and London.

ProfitLogic is a company specializing in the development and marketing of retail profit optimization software solutions. Established in 1983 and based in Cambridge, Massachusetts, it provides a comprehensive suite of applications designed to assist retailers in making informed decisions regarding allocation, planning, pricing, and inventory management. Its offerings encompass various aspects of retail operations, including assortment and allocation, pricing strategies, promotions and marketing, as well as performance assessment and management. Through its innovative software solutions, ProfitLogic aims to enhance profitability across all retail verticals. The company was previously known as Technology Strategy, Inc. (TSI).

deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.

ProfitLogic is a company specializing in the development and marketing of retail profit optimization software solutions. Established in 1983 and based in Cambridge, Massachusetts, it provides a comprehensive suite of applications designed to assist retailers in making informed decisions regarding allocation, planning, pricing, and inventory management. Its offerings encompass various aspects of retail operations, including assortment and allocation, pricing strategies, promotions and marketing, as well as performance assessment and management. Through its innovative software solutions, ProfitLogic aims to enhance profitability across all retail verticals. The company was previously known as Technology Strategy, Inc. (TSI).

deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.

Marathon Technologies Corporation specializes in fault-tolerant and disaster recovery software solutions tailored for both physical and virtual servers. The company’s primary offerings include everRun VM, which safeguards against outages and data loss in Citrix virtual server environments; everRun HA, designed for component-level fault tolerance to protect Windows server applications; and everRun FT, which ensures system-level fault tolerance for high availability of Windows applications. Additionally, Marathon Technologies provides everRun SplitSite to enhance geographic fault tolerance and mitigate risks from localized and site-wide disasters, along with everRun CDP & DR, a software solution for disaster recovery planning that captures and replicates application data to prevent catastrophic failure. The company also extends consulting, training, and technical support services to its diverse clientele, which includes broadcast networks, corporate organizations, pharmaceutical firms, casino properties, and midsized companies. Founded in 1993, Marathon Technologies is headquartered in Littleton, Massachusetts.

Solect Energy, located in Hopkinton, Massachusetts, is a prominent leader in the commercial-scale solar sector. The company specializes in providing solar energy solutions tailored for businesses, emphasizing the development, design, and implementation of solar projects that enhance sustainability and reduce energy costs. With a commitment to advancing renewable energy, Solect Energy plays a significant role in helping organizations transition to cleaner energy sources, contributing to both environmental goals and economic benefits. Through its expertise and innovative approach, the company has established itself as a key player in the growing solar energy market.

Cortera, Inc. is a provider of business-to-business analytics and cloud-based risk management solutions, specializing in payment and purchase behavior data for public and private companies. Founded in 1993 and headquartered in Boca Raton, Florida, with additional offices in Massachusetts and India, Cortera tracks $1.6 trillion in business-to-business purchases across 45 categories, offering insights on 20 million U.S. business locations. The company's products include Cortera Pulse, a subscription service for monitoring credit risk; Boost, which enhances customer insights; and Cortera Decisions, an automated scorecard platform. Additionally, Cortera offers eCredit for credit scoring and collections automation, Cortera Traits for real-time statistical modeling, and Connect, an XML web service for accessing proprietary data. These solutions help businesses of all sizes understand their customers and suppliers better, ultimately aiding in revenue growth and risk reduction.